XB-ART-45397Proc Natl Acad Sci U S A. July 10, 2012; 109 (28): E1947-56.
Dynamics of TGF-β signaling reveal adaptive and pulsatile behaviors reflected in the nuclear localization of transcription factor Smad4.
PubMed ID: 22689943
PMC ID: PMC3396545
Article link: Proc Natl Acad Sci U S A.
Grant support: R01 HD32105 NICHD NIH HHS , R01 GM101653 NIGMS NIH HHS , R01 HD032105 NICHD NIH HHS
Genes referenced: hist2h2be nodal nodal1 smad1 smad2 smad4.1 smad4.2 smad7
Article Images: [+] show captions
|Fig 1. Smad2 activation is stable under continuous stimulation. (A) Constructs used to generate the RFP-Smad2 cell line. Triangles denote the ePiggyBac terminal repeats, arrows denote promoters, and gray boxes denote antibiotic resistance genes. (B) Images of live untreated cells (Upper) or cells treated with 5 ng/mL TGF-β1 for 1 h (Lower) showing accumulation of RFP-Smad2 in the nucleus upon TGF-β1 treatment. (C) Quantification of average nuclear RFP-Smad2 from live cell imaging in cells exposed first to 5 ng/mL TGF-β1 and then exposed to 10 uM SB431542 1 h later, showing that pathway inhibition results in relocalization of RFP-Smad2 to the cytoplasm (D) Time courses of nuclear RFP-Smad2 show stable nuclear accumulation in cells exposed to either high (5 ng/mL) or low (0.1 ng/mL) doses of TGF-β1. Black lines represent averages of all cells in the field of view (>50 cells). Colored lines represent selected single cells. Cell nuclei were identified automatically and tracked through time using the GFP-NLS nuclear marker. (E) Immunofluorescent staining for Smad2/3 at the indicated times after continuous application of 1 ng/mL TGF-β1 showing stable enrichment of endogenous Smad2/3 in the nucleus. (F) Western blots of total cell lysates from cells continuously exposed to 5 ng/mL TGF-β1 for the indicated times show stably elevated pSmad2/3 levels|
|Fig 3. Smad4 adapts to a step in ligand concentration, and Smad4 nuclear localization coincides with transcription. (A) Constructs used in generating the Smad4 cell line. Notation is as in Fig. 1A. (B) Snapshots from a time-lapse movie of cells exposed to 5 ng/mL TGF-β1 at time t = 0. Smad4 is enriched in the nucleus after 1 h but becomes mostly cytoplasmic by 4 h. (C) Quantification of single-cell trajectories (colored lines) and average trajectory (black line). (D) Comparison of average RFP-Smad2 and GFP-Smad4 fluorescence in the nucleus as a function of the duration of continuous TGF-β1 treatment. Smad2 nuclear accumulation is sustained, whereas Smad4 is transient. (E) Smad4 amplitude but not kinetics is dependent on the dose of TGF-β1 ligand. Comparison of average nuclear to cytoplasmic GFP-Smad4 in cells treated with either 0.1 or 5 ng/mL TGF-β1. (F) Smad4 kinetics does not require continuous signaling. C2C12 GFP-Smad4 Cells were treated with 5 ng/mL TGF-β1 only or with 5 ng/mL TGF-β1 and then with 10 μM SB431542 1 h later. Traces show average nuclear fluorescence as a function of time.|
|Fig 4. Smad4 adaptation requires new protein synthesis, and transcriptional dynamics correlate with Smad4 but not Smad2 nuclear accumulation. (A) Snapshots from time-lapse imaging of GFP-Smad4 cells treated with TGF-β1 and cycloheximide showing sustained nuclear accumulation of Smad4. (B) Quantification of the average ratio of nuclear to cytoplasmic GFP-Smad4 in cells treated with TGF-β1 and either cycloheximide or MG132. Smad4 adaptation requires new protein synthesis but not protein degradation. (C) Quantification of nuclear RFP-Smad2 in cells treated with TGF-β1 and either MG132 or cy- cloheximide. Inhibition of protein synthesis leads to loss of Smad2 from the cell nucleus, whereas inhibition of the proteasome results in continued accu- mulation of Smad2 in the cell nucleus. (D and E) Expression of TGF-β target genes by qRT-PCR as a function of duration of treatment in the GFP-Smad4 C2C12 cell line treated with TGF-β1 and either cycloheximide (chx) (D) or MG132 (E). Inhibiting the proteasome has little effect on dynamics, whereas inhibiting protein synthesis converts the transient response to a sustained one. The increase in Smad7 at long treatment with MG132 may be a homeostatic response to high levels of Smad2 that accumulate after prolonged MG132 treatment (see C).|
|Fig 5. Smad1 is homogeneously activated, whereas Smad4 is heterogeneous and exhibits brief bursts of nuclear localization in Xenopus animal cap explants. (A) Smad1 phosphorylation but not Smad1 localization responds to inhibition of BMP signaling. Images are of animal pole tissue from embryos injected at the two-cell stage with 100 pg GFP-Smad1 mRNA and 100 pg mCherry-H2B mRNA in each cell. At stage 9 embryos were fixed and stained by immunofluorescence for pSmad1/5/8. (B) Quantification of average nuclear-to-cytoplasmic ratios from the images in A. GFP-Smad1 localization does not depend on BMP signaling. (C) Smad4 localization is heterogeneous. Images of a stage-9 animal cap explant from an embryo injected at the two-cell stage with 50 pg per cell of Venus- Smad4 mRNA and 100 pg per cell of mCherry-H2B mRNA. (D) Zoomed-in image showing the pulses in single cells. (Upper) A cell that pulses without dividing. (Lower) A cell that divides during the pulse.|
|Fig 6. Pulses of nuclear Smad4 can be induced by either BMP or activin/nodal signaling in Xenopus animal cap explants. (A) Pulses are dependent on endogenous BMP signaling. Image of a stage-9 animal cap explant in which 50 pg Venus Smad4 and 100 pg mCherry-H2B mRNA were coinjected with 1 ng of the BMP inhibitor DNAlk3 mRNA. The animal cap explant shown is from a sibling embryo of the one used to make the explants shown in Fig. 5 C and D with injections and imaging performed at the same times. (B) Quantification of number of pulses and pulse height and duration. (C) Quantification of single-cell traces from the time-lapse movies. (D) Response of Smad4 to activin treatment. Embryos were injected in the animal pole with Venus-Smad4, mCherry-H2B, and DNAlk3 mRNAs to inhibit BMP signaling. Animal cap explants were dissected at stage 9 and treated with activin. Pictures are shown before (Left) or 45 m after (Right) activin treatment. (E) Quantification of number of bursts in animal cap explants injected with Venus-Smad4 and DNAlk3 and either left untreated or treated with activin (10 ng/mL).|